Literature DB >> 1681649

Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat.

J Faergemann1, H Zehender, T Jones, I Maibach.   

Abstract

We determined terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat before, during and after 250 mg doses orally to volunteers once daily. Terbinafine is concentrated rapidly in stratum corneum (up to 9.1 micrograms/g of tissue) primarily by diffusion from the vascular system through the dermisepidermis. It also reaches high concentration in sebum (up to 45.1 micrograms/ml) after several days and continue to concentrate in sebum for up to two days after discontinuation of drug. Hair concentration reach levels of 2.6 micrograms/g of tissue indicating high drug levels in and around the hair follicle. It is not found in sweat. Plasma levels range between 0.1 and 1.0 micrograms/ml. There is a tenfold accumulation of drug in stratum corneum by day 2. Elimination of drug from tissue occurs with a half-life of 4 to 5 days and with the potential for drug levels above fungicidal concentrations for dermatophytes for more than 3 weeks. The tissue pharmacokinetic profile of terbinafine is similar to that of another lipophilic drug, itraconazole, but is very different from ketoconazole and griseofulvin. Higher levels of terbinafine are achieved than of either of the imidazoles and remain longer than griseofulvin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1681649

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  18 in total

Review 1.  Drugs in nails: physiology, pharmacokinetics and forensic toxicology.

Authors:  A Palmeri; S Pichini; R Pacifici; P Zuccaro; A Lopez
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man.

Authors:  I Alberti; Y N Kalia; A Naik; R H Guy
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

Review 3.  Onychomycosis. Going for cure.

Authors:  A K Gupta; N H Shear
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

Review 4.  Tinea gladiatorum: wrestling's emerging foe.

Authors:  T D Kohl; M Lisney
Journal:  Sports Med       Date:  2000-06       Impact factor: 11.136

Review 5.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

6.  MIC and Upper Limit of Wild-Type Distribution for 13 Antifungal Agents against a Trichophyton mentagrophytes-Trichophyton interdigitale Complex of Indian Origin.

Authors:  Dipika Shaw; Shreya Singh; Sunil Dogra; Jyothi Jayaraman; Ramesh Bhat; Saumya Panda; Arunaloke Chakrabarti; Nishat Anjum; Aruna Chowdappa; Mahantesh Nagamoti; Umesh Varshney; Hari Pankaj Vanam; Jayanthi Savio; Meryl Antony; Shivaprakash M Rudramurthy
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 7.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial.

Authors:  Saeedeh Farajzadeh; Amireh Heshmatkhah; Behrooz Vares; Elham Mohebbi; Azadeh Mohebbi; Mahin Aflatoonian; Sana Eybpoosh; Iraj Sharifi; Mohammad Reza Aflatoonian; Simin Shamsi Meymandi; Ali Reza Fekri; Mahshid Mostafavi
Journal:  J Parasit Dis       Date:  2015-01-22

9.  Safety and efficacy of terbinafine in a pediatric Iranian cohort of patients with Tinea capitis.

Authors:  Ali M Sabzghabaee; Parwin Mansouri; Mahboobeh Mohammadi
Journal:  Saudi Pharm J       Date:  2009-08-07       Impact factor: 4.330

Review 10.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.